Notice of Allowability	Application No.	Applicant(s)	
	10/796,673	UENO ET AL.	
	Examiner	Art Unit	
	Sudhaker B. Patel, D.Sc.Tech.	1624	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. This communication is responsive to <u>3/10/04</u> .			
2. ☑ The allowed claim(s) is/are <u>1-7 and 10</u> .			
3. The drawings filed on are accepted by the Examiner.			
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 09/509,778. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 			
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.			
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.			
 CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 			
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.			
 Attachment(s) 1. ☑ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 3/10/04 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material 	5. ☐ Notice of Informal P. 6. ☑ Interview Summary Paper No./Mail Dat 7. ☑ Examiner's Amendn 8. ☑ Examiner's Stateme 9. ☐ Other	(PTO-413), e <u>8/12/04</u> . nent/Comment	

Application/Control Number: 10/796,673

Art Unit: 1624

REASONS FOR ALLOWANCE

- 1. The following is an examiner's statement of reasons for allowance:
- 2. Applicants have cancelled claims 8, 9(See interview summary dated 8/12/04, and examiner's amendment). Therefore, the claims under consideration are the claims 1-8,10, which are renumbered as claims 1-8 respectively.
- 3. The closest reference(s) prior art(s) of record (see the parent case U.S. Application Sr. # 09852850 filed 5/11/01, now allowed) Aebi et al (CH432808), Nair et al (Chemical Abstract DN 77:"164414), and Simmonds et al (GB 1545767) teach utility and making of compounds with isoquinoline core wherein the 3-position is occupied by amino and 4-position is occupied by –CH3 groups.
- 4. The references either alone or in combination do not indicate or suggest to arriving at the instant compounds wherein the instant 3-position of modified basic core of isoquinoline (or pyridino-pyridine) is occupied by a bridge –(CH2) n-Aryl/Aralkoxy/4-phenylpiperidin-1-yl, 1-position R2 is piperazine, and the 4-position R3 is Hydrogen.
- 5. Therefore, the compounds of instant invention are deemed to be novel and patentably distinct.
- 6. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
- 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sudhaker B. Patel, D.Sc.Tech. whose telephone number is (571) 272-0671.
- 8. The examiner can normally be reached on 6:30 to 5:00 pm (Monday-Thursday). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Mukund J. Shah can be reached on (571) 272 0674 or Sr. Examiner Mr. Richard Raymond at (571) 272 0673 or Mr. James O. Wilson at (571) 272-0661.
- 9. The fax phone numbers for the organization where this application or proceeding is assigned are 703 308 4556 for regular communications and 703 308 4556 for After Final communications.
- 10. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308

Page 2

1235.Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published

applications may be obtained from either Private PAIR or Public PAIR. Status

information for unpublished applications is available through Private PAIR only. For

more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

have questions on access to the Private PAIR system, contact the Electronic Business

Center (EBC) at 866-217-9197 (toll-free).

Sudhaker B. Patel, D.Sc. Tech.

August 12, 2004

MUKUNBRSUMNI 624

SUPERVISORY PATENT

EXAMINER

ART UNIT 1624/1623

Application/Control Number: 10/796,673

Art Unit: 1624

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with ATTY. Mr. J. Bailey on 8/12/04.

The application has been amended as follows:

(1). Please cancel claims 8, 9.

8/12/04